Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

These findings open up new approaches for managing conditions like ... and glucagon, both produced by the pancreas. Insulin lowers blood glucose by promoting its uptake into cells, while glucagon ...

In our January research highlights, we look at new research into how AI-powered screening could spot type 2 diabetes risk years in advance, and a new study into genetically altered beta cell therapy ...